Somewhat Positive Press Coverage Somewhat Unlikely to Impact Endologix (ELGX) Share Price

News articles about Endologix (NASDAQ:ELGX) have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endologix earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 44.7806277690488 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

Several equities research analysts have weighed in on the company. ValuEngine downgraded Endologix from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Oppenheimer Holdings, Inc. set a $5.00 price target on Endologix and gave the stock a “hold” rating in a research report on Thursday, August 3rd. Stifel Nicolaus set a $6.00 price target on Endologix and gave the stock a “hold” rating in a research report on Friday, October 6th. Zacks Investment Research raised Endologix from a “hold” rating to a “strong-buy” rating and set a $5.75 price target on the stock in a research report on Monday, July 24th. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and set a $5.00 price target on shares of Endologix in a research report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating and eleven have given a hold rating to the company. Endologix has a consensus rating of “Hold” and a consensus price target of $6.28.

Endologix (ELGX) traded up 1.38% during midday trading on Thursday, hitting $5.16. 357,266 shares of the stock traded hands. The company’s 50 day moving average is $4.62 and its 200-day moving average is $5.30. The company’s market cap is $430.52 million. Endologix has a one year low of $4.08 and a one year high of $13.17.

Endologix (NASDAQ:ELGX) last issued its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.08. Endologix had a negative net margin of 40.77% and a negative return on equity of 46.32%. The company had revenue of $48.60 million for the quarter, compared to analyst estimates of $47.58 million. During the same period in the prior year, the business posted ($0.20) earnings per share. The firm’s revenue for the quarter was down 4.6% compared to the same quarter last year. On average, equities research analysts forecast that Endologix will post ($0.62) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/10/12/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-endologix-elgx-share-price.html.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Insider Buying and Selling by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply